MiNK Therapeutics (NASDAQ:INKT) Trading Up 1.7% – Time to Buy?

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares traded up 1.7% during trading on Monday . The company traded as high as $10.62 and last traded at $10.45. 6,483 shares traded hands during mid-day trading, an increase of 41% from the average session volume of 4,587 shares. The stock had previously closed at $10.28.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Stock Up 1.7%

The firm’s fifty day moving average price is $11.54 and its two-hundred day moving average price is $12.78. The stock has a market capitalization of $49.01 million, a PE ratio of -3.45 and a beta of 0.35.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC raised its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.